CJC-1295 and ipamorelin are two synthetic peptides that work together to stimulate your body’s natural production of growth hormone. They’re typically combined into a single injection and used to support fat loss, muscle recovery, and sleep quality. Neither peptide is FDA-approved, and both sit in a regulatory gray area that’s important to understand before considering them.
How the Two Peptides Work Together
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH), the signal your brain naturally sends to the pituitary gland to produce growth hormone. Ipamorelin works through a different pathway: it mimics ghrelin, another hormone that triggers growth hormone release. By targeting two separate receptors on the pituitary gland simultaneously, the combination produces a stronger and more sustained pulse of growth hormone than either peptide would alone.
In clinical testing, a single injection of CJC-1295 increased average growth hormone levels by 2 to 10 times for six or more days, and raised IGF-1 (a downstream marker of growth hormone activity) by 1.5 to 3 times for 9 to 11 days. Multiple doses showed a cumulative effect, meaning levels continued building over time. Ipamorelin’s role in the pairing is to amplify that pulse while being relatively selective in what it triggers. Unlike some older growth hormone-releasing peptides, ipamorelin doesn’t cause large spikes in cortisol or prolactin, which makes the side effect profile milder.
CJC-1295 With DAC vs. Without DAC
You’ll often see CJC-1295 sold in two forms: with DAC and without DAC. DAC stands for Drug Affinity Complex, a chemical modification that lets the peptide bind to a blood protein called albumin. This dramatically extends its half-life to roughly 6 to 8 days, meaning growth hormone stays elevated for much longer after each injection.
The version without DAC (sometimes called Mod GRF 1-29) has a half-life of only about 30 minutes. That short window creates a sharper, more defined pulse of growth hormone that more closely mimics the body’s natural release pattern. When people talk about the “CJC-1295/ipamorelin blend,” they almost always mean the no-DAC version, because it pairs better with ipamorelin’s similarly short action. The two are injected together, usually at bedtime, to amplify the natural growth hormone surge that occurs during deep sleep.
What to Expect and When
Results from the combination follow a fairly predictable timeline when paired with consistent exercise and nutrition. The first changes most people notice are improvements in sleep quality and post-workout recovery, typically within the first one to four weeks. Energy and mood tend to stabilize during this same window, though visible body composition changes are still subtle.
By months two and three, fat loss becomes more apparent, particularly around the midsection. Muscle definition starts to sharpen, workout endurance improves, and some people report better skin tone and mental focus. Between months four and six, lean muscle gains become more noticeable alongside continued fat loss, and many users describe improvements in skin elasticity and hair quality. After six months of consistent use, the cumulative effect is a meaningful shift in body composition: lower body fat percentage, more lean muscle, and sustained energy levels.
These peptides are not a shortcut. The results depend heavily on your training, diet, and sleep habits. Without those foundations, the effects are minimal.
How It’s Typically Used
The combination is commonly supplied as a premixed solution containing 1 mg of CJC-1295 and 1 mg of ipamorelin per milliliter, though 2 mg/2 mg and 2 mg/1 mg concentrations also exist. A typical protocol involves a small subcutaneous injection (0.05 to 0.1 mL) at bedtime, five days per week with two days off. The injection is given on an empty stomach, at least two to three hours after your last meal, because food (especially carbohydrates and fats) can blunt the growth hormone response.
Most protocols run for three to six months, sometimes with planned breaks to prevent the pituitary gland from becoming desensitized. The bedtime timing is intentional: it stacks on top of the body’s largest natural growth hormone pulse, which occurs during the first phase of deep sleep.
Side Effects
At lower doses, CJC-1295 has been described in clinical research as “safe and relatively well tolerated.” The most commonly reported side effects are mild: injection site redness or irritation, temporary flushing, and occasional headaches. Some people experience water retention or tingling in the hands and feet, both related to increased growth hormone activity.
The more serious concerns are less about the peptides themselves and more about how they’re made. Because these are compounded products (mixed by specialty pharmacies rather than manufactured by pharmaceutical companies), quality can vary significantly. The FDA has flagged both CJC-1295 and ipamorelin for potential immunogenicity risks, meaning improperly made batches could contain impurities that trigger immune reactions. The FDA also noted that CJC-1295 has been associated with increased heart rate and blood vessel dilation in some cases, and that a published study linked intravenous ipamorelin administration to serious adverse events including death, though that involved a different route and clinical context than the subcutaneous injections used in peptide therapy.
Regulatory Status
Neither CJC-1295 nor ipamorelin is FDA-approved for any medical use. They’ve historically been available through compounding pharmacies, which can legally prepare custom medications under certain conditions. However, the FDA has placed both peptides on a list of bulk drug substances that may present significant safety risks when compounded.
The FDA’s concerns center on three issues: limited clinical data in humans, the complexity of manufacturing peptides without impurities, and the fact that ipamorelin contains unnatural amino acids that make quality testing more difficult. This regulatory scrutiny has made access increasingly restricted. Some clinics that previously offered the combination have shifted to alternative peptides, while others continue to prescribe it under state-level compounding regulations. The legal landscape is actively shifting, so availability depends heavily on where you live and what your prescribing provider has access to.
If you’re considering this combination, the source of the product matters as much as the peptides themselves. A compounding pharmacy operating under proper oversight is a very different situation from a gray-market research chemical supplier, and the risks change accordingly.